ClinicalTrials.gg
CompletedNCT01520831Updated Jan 4, 2017

Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects

A Phase 1 interventional study of biphasic insulin aspart 30 and biphasic insulin aspart 50 in Diabetes and Healthy, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2017-01-04.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 142 studies testing Insulin Aspart in Diabetes Mellitus — 1 open to participants now, 1 under way, 1 of them phase 3. Insulin Aspart · Diabetes Mellitus.

Enrollment
101st of 142
35 · median 80
Started
1999
with 3 others
Phase 1
46 of 142
none open now
Registered
82nd of 142
by date
Lead sponsor
123 of 142
Novo Nordisk A/S

Among the 142 studies testing Insulin Aspart in Diabetes Mellitus, this one is the 101st largest by enrollment, is one of 4 that started in 1999, is one of 46 in phase 1, and was the 82nd registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 142 studies testing Insulin Aspart in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin Aspart

Insulin Aspart: first FDA approval 2000 (NOVOLOG PENFILL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies testing Insulin Aspart in Diabetes Mellitus, or all of them as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to demonstrate a difference between the pharmacodynamics and pharmacokinetics of biphasic insulin aspart 30, biphasic insulin aspart 50, biphasic insulin aspart 70 and insulin aspart in healthy subjects.

03

Conditions studied

  • Diabetes
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18 and 28 kg/m\^2 inclusive
  • within the normal laboratory range
  • Non smoker for at least three months
  • Females of using acceptable methods of , including tubal ligation, an intrauterine device (IUD) , the oral contraceptive pill or barrier methods

Exclusion criteria

Exclusion Criteria:

  • Subjects who have received any drug in the 3 months prior to the start of dosing
  • Any disease requiring regular use of non topical prescription medicines
  • Any serious systemic infectious disease that occurred in the 4 weeks prior to the first dose of test drug
  • Any intercurrent illness or endocrine disorders that may affect blood glucose
  • Subject with a history of drug or alcohol dependence
  • Subject with a first degree relative with diabetes mellitus
  • Subject with a history of allergic reactions to medical products
  • Subjects who have donated any blood or plasma in the past 3 month preceding screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    BIAsp 30

    Drug: biphasic insulin aspart 30

  • Experimental
    BIAsp 50

    Drug: biphasic insulin aspart 50

  • Experimental
    BIAsp 70

    Drug: biphasic insulin aspart 70

  • Active comparator
    Insulin aspart

    Drug: insulin aspart

Interventions

  • Drugbiphasic insulin aspart 30

    One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days

  • DrugInsulin AspartStudies of Insulin AspartInsulin Aspart pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days

  • DrugInsulin AspartStudies of Insulin AspartInsulin Aspart pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days

  • One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days

06

What researchers measure

Primary outcomes

  1. Area under the GIR (Glucose Infusion Rate) profile (AUC GIR) in the interval 0-120 minutes

Secondary outcomes

  1. Maximum GIR value

  2. Time to maximum GIR value

  3. Area under the GIR profile

  4. Cmax, maximum insulin aspart concentration

  5. Area under the insulin aspart concentration curve

  6. tmax, the time to maximum insulin aspart concentration

  7. t½, terminal half-life

07

Study locations

1 site
  • Novo Nordisk Investigational Site
    Neuss, 41460, Germany
08

References and documents

Publications

  • Heise T, Kapitza C, Jacobsen LV, Brøndsted L, Heinemann L. Pharmacokinetic and pharmacodynamic differences between premixed suspensions of insulin aspart: biphasic insulin aspart 30, 50 and 70. Diabetologia 2005; 48 (Suppl. 1): A301
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 1999, a primary completion of May 2000 and a completion of May 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2012
First posted
Jan 30, 2012
Start
Apr 1999
Primary completionActual
May 2000
CompletionActual
May 2000
Last update
Jan 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01520831
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 30, 2012
Start date
Apr 1999
Primary completion
May 2000
Completion
May 2000
Last update
Jan 4, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Aspart

Start the discussion